Adipose tissue-secreted miR-27a promotes liver cancer by targeting FOXO1 in obese individuals

Abstract: The current notion that obesity is a major risk factor for the development of and the mortality associated with a subset of liver cancer is well appreciated. However, detailed mechanistic insights underlying this relationship are lacking. Better understanding of the adipose tissue-secreted miRNAs that play a potential role in defining primary liver cancer development and mediating the obesity-cancer communication offers the potential for new insights into tumor growth and interventions to modulate tumor formation and progression. In this study, we clearly demonstrated that miR-27a is more highly upregulated in cancer, plasma, and adipose samples from obese liver cancer cases, and therefore reasoned that miR-27a excreted from adipose tissue leads to liver cancer development. To address this idea, we prepared miR-27a-overexpressing 3T3-L1 adipocytes and cocultured them with HepG2 liver cancer cells. Our results demonstrated that secretory miR-27a promoted liver cancer cell proliferation through the downregulation of the transcription factor FOXO1 and promoted the G1/S cell cycle transition by decreasing the cell cycle inhibitors p21 and p27 and increasing the cell cycle regulator cyclin D1. These findings improve our understanding of the involvement of miR-27a in obesity-liver cancer communication and might provide a novel putative target for obesity-driven primary liver cancer diagnosis and therapy.

Keywords: miR-27a, primary liver cancer, obesity, adipose tissue, FOXO1

Introduction

Primary liver cancer is the fifth most commonly diagnosed malignancy in men and remains the third leading cause of cancer death in the world. Liver cancer has been primarily associated with cirrhosis due to chronic infection by the hepatitis B virus (HBV) and the hepatitis C virus (HCV), genetic disorders such as hemochromatosis, or toxic injury from excessive alcohol consumption. Though a substantial number of cases cannot be explained by these etiologies, primary liver cancer is increasingly diagnosed among obese individuals. In many developed nations, obesity has been recognized as a key component of metabolic syndrome. The accrual of excess adipose tissue during obesity is associated with the dysfunction of this tissue, which can predispose individuals to develop type 2 diabetes mellitus (T2DM) as well as cardiovascular disease. Moreover, patients with obesity are widely accepted to be at an increased risk of the development and progression of several cancers, including breast, gastrointestinal, renal, esophageal, and reproductive cancers. The increased risk of primary liver cancer that is associated with obesity has been widely reported, this has drawn much attention and, as such, warrants investigation of the key mechanisms that link the obese state with hepatocarcinogenesis.

Obesity-associated primary liver cancer has recently been attributed to molecular mechanisms such as chronic inflammation due to adipose tissue remodeling, ectopic lipid accumulation and lipotoxicity, proinflammatory adipokine secretion altered...
Adipose tissue within the tumor microenvironment actively contributes to tumor growth and metastasis by functioning as an endocrine organ through the secretion of signaling molecules (such as adipokines, proangiogenic factors, proinflammatory cytokines, and extracellular matrix constituents) and acting as an energy reservoir for embedded cancer cells.11–13 Thus, the importance of adipose tissue as an integral contributor to cancer progression is increasingly appreciated. Understanding the key molecular features of obesity-induced dysfunctional adipose tissue might, therefore, offer important mechanistic insights into the relationship between obesity and primary liver cancer.

Intercellular communications are an essential part of the relationship between cells that enable normal cellular function and maintain tissue homeostasis.14 As recently as a few years ago, it was believed that RNAs could not behave as extracellular signal molecules because of their vulnerability to the attack of ribonucleases, which largely exist in the body fluid. Evidence showing that microRNAs (miRNAs) are contained in exosomes that are released from mammalian cells and act as signal transducers is presently increasing.15,16 MiRNAs are a class of small noncoding RNA (22 nt) that regulate gene expression by binding to the 3′-untranslated region (3′-UTR) of target genes, thus triggering message RNA (mRNA) degradation or protein translation inhibition.17,18 Adipocytes have been reported to secrete miRNAs contained in exosomes, which many may regulate the function of distant or neighboring cells during obesity.19 The Ogawa group reported that exosomes released from cultured 3T3-L1 adipocytes harbored 143 miRNAs, most of which are adipocyte-specific and reflect the abundance of their expression levels in the donor cells.20 Based on these observations, we reasoned that the miRNAs excreted from adipose tissue could be increased in obesity, leading to the increased stimulation of liver cancer development.

To address these issues, we first studied miR-27a expression using tumor tissue, adipose tissue, and plasma samples from obese liver cancer patients, nonobese liver cancer patients, and healthy individuals. Next, we transfected 3T3-L1 cells with a miR-27a overexpression plasmid and investigated whether miR-27a released from adipose cells transfers proliferation signals to liver cancer cells in a coculture experiment. Our results test the hypotheses that miR-27a, which is characteristically overexpressed and secreted by adipose tissue during obesity, is a potent regulator of liver cancer proliferation by targeting the forkhead transcription factor 1 (FOXO1).

Materials and methods

Clinical samples

Thirty paired liver cancer tissue samples (T) compared with matched adjacent normal tissue (ANT) samples were collected during routine therapeutic surgery of nonobese (n=15) and obese (n=15) hepatocellular carcinoma (HCC) patients in our hospital. Written informed consent was obtained from each patient. Omental adipose tissues were also obtained from the same patient. This work was approved by the Ethics Committee of China-Japan Union Hospital of Jilin University. All tissues were immediately frozen in liquid nitrogen after explantation. Plasma samples from healthy people (controls, n=10) were collected from our department. People without any current clinical conditions and without a family history of diseases such as cancer, HIV, diabetes, and autoimmune diseases were qualified as healthy individuals. Body mass index (BMI) was calculated as weight divided by height in meter squared.

Cell culture and transfection

The mouse embryo 3T3-L1 cell line and the human liver cancer HepG2 cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco, Carlsbad, CA, USA) with high glucose content, supplemented with 10% fetal bovine serum (FBS) (Gibco), 100 units/mL penicillin, and 100 μg/mL streptomycin. All of the cells were incubated at 37°C in a humidified chamber containing 5% CO2. The miR-27a overexpression plasmid and the control vector were from GeneCopoeia (Rockville, MD, USA). To establish stable miR-27a-overexpressing 3T3-L1 cell lines, approximately 1×10⁶ cells were seeded and cultured in 35 mm cell culture dishes. When the cells reached 90%–95% confluence, 50 μg of the miR-27a plasmid was transfected with Lipofectamine 2000 (Invitrogen Life Technologies, Waltham, MA, USA) according to the manufacturer’s instructions. The transfected cells were incubated at 5% CO2 and 37°C. Four hours later, the transfection media was changed to DMEM containing 10% FBS. Twelve hours after transfection, the cells were replated in a 10-cm dish followed by a 3-week selection with antibiotic. Ten surviving single colonies were picked up from each transfectant and then cultured for another 2 weeks. The cells expressing the largest amount of miR-27a among the transfectants were used as miR-27a stably expressing cells.
miRNA isolation and quantitative real-time polymerase chain reaction

Total RNA and miR fractions were isolated from tissue samples, serum, and HepG2 cell lines with TRIzol reagent (Invitrogen). RNA was reverse transcribed into cDNA with TransScript First-Strand cDNA synthesis supermix (TransScript, Invitrogen), following the manufacturer’s instructions. MicroRNA extraction was performed using the miRNA Extraction Kit (Tiangen, Beijing, People’s Republic of China). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using a FastStart Universal STBR Green Master (Roche) from Basel, Switzerland). Primers of miR-27a and U6 were obtained from Ribobio (Guangzhou, People’s Republic of China). The expression of miR-27a was normalized with U6 using the 2-ΔΔCT method. The miRNA expression levels were defined based on the threshold cycle (Ct) and the relative expression levels were calculated as 2-\[(Ct \text{ of } \text{miR-27a}) - (Ct \text{ of } \text{U6})\].

RT-PCR was performed using the Applied Biosystems 7,300 Sequence Detection system using the following primers for FOXO1, (forward, 5'-ACATTTGGCTCTCAGACCTCAG-3' and reverse, 5'-ATTTCTGACAGACCTGGCACG-3'); p21, (forward, 5'-CGATGACCTCACCTGCTTCAGA-3' and reverse, 5'-TCGAGACCTCCAGATG-3'); p27, (forward, 5'-TCGACGGGATCCTTCTTACTCAA-3' and reverse, 5'-CCACGAGGGATGTATCTGAT AAACAAGGA-3'); and cyclin D1 mRNA (forward, 5'-AAGCCTGGACACCTTGCTTCAA-3' and reverse, 5'-TCGACGGGATGTAATCTCAGAAC-3'). The expression data were normalized to the geometric mean expression level of the housekeeping gene GAPDH (forward, 5'-GACTCATGACCACGATGC-3' and reverse, 3'-AGAGCGCGCTGATGCTTGT-5') and calculated using 2-\[(Ct \text{ of FOXO1, p21, p27, or cyclin D1}) - (Ct \text{ of GAPDH})\], where Ct represents the threshold cycle for each transcript.

Coculture experiment and MTT assay

miR-27a inhibitors and mimics were obtained from RiboBio. In coculture experiments, 2×10⁴ cells/well of miR-27a-overexpressed-3T3-L1 cells were plated in 6-well plates. After 12 hours, 1×10⁵ HepG2 cells were seeded in transwell and cocultured with miR-27a-overexpressed-3T3-L1 cells at 37°C. To the medium, 100 nM miR-27a inhibitor was added. After coculture for 24 or 48 hours, cell medium was collected, and the cells were incubated in 0.1 mg/mL MTT at 37°C for 3 hours and lysed in dimethyl sulfoxide (DMSO) at room temperature for 30 minutes. The absorbance in each well was measured at 570 nm using a microplate reader. Each experiment was performed in triplicate. The survival rate of cells was expressed as A/B 100%, where A was the absorbance value from the experimental cells and B was that from the control cells.

Cell cycle analysis

Cells were collected by trypsinization, washed in ice-cold PBS, and fixed in 80% ice-cold ethanol in PBS. Before staining, the cells were pelleted by centrifugation at 4°C and resuspended in chilled PBS, followed by incubation with 20 μg/mL of propidium iodide (Sigma-Aldrich, St Louis, MO, USA) for 20 minutes at room temperature. Fifty thousand cells per group were analyzed on a flow cytometer (FACS Calibur; BD Biosciences, San Jose, CA, USA).

Western blot analysis

Cells were harvested and lysed with ice-cold lysis buffer containing 50 mM Tris-HCl, pH 6.8, 100 mM 2-mercaptoethanol, 2% w/v sodium dodecyl sulfate, and 10% glycerol. After centrifugation, the supernatants were quantified and separated by 10% SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and transferred to a nitrocellulose membrane (Amersham Bioscience, Buckinghamshire, UK). After blocking with 10% nonfat milk in Tris-buffer saline (TBS), membranes were immunoblotted with antibodies, followed by HRP-linked secondary antibodies. Detection of antibody binding was performed using the enhanced chemiluminescence kit (Amersham Pharmacia Biotech, Amersham, UK). All western blot analyses were repeated three times. Anti-FOXO1, anti-cyclin D1, anti-p27, and anti-p21 were purchased from Santa Cruz Biotechnologies, Inc. (Santa Cruz, CA, USA). Protein levels were normalized to total GAPDH, using a rabbit polyclonal anti-GAPDH antibody (Santa Cruz Biotechnologies, Inc.).

Immunohistochemistry

Immunohistochemical staining for FOXO1, p21, p27, and cyclin D1 in the above-mentioned 30 HCC samples was performed following the methods described previously. Briefly, after deparaffinization and blocking, the sections were incubated overnight at 4°C with the antibody. The sections were counterstained with Meyer’s hematoxylin. FOXO1, p21, p27, and cyclin D1-positive cells were defined as those with brown staining in the nucleus and cytoplasm, respectively. Signals in tumor tissue and matched ANT were visually quantified using the same scoring system (0–9), multiplied intensity of signal, and percentage of positive
cells (signal: 0=no signal, 1=weak signal, 2=intermediate
signal, and 3=strong signal; percentage: 0=0%, 1=<25%,
2=25%–50%, and 3=>50%).

Statistical analysis
All experiments were completed at least three times unless
otherwise indicated. Data are expressed as the means ±
standard deviations. The two-tailed Student’s t-test was used
to evaluate the significance of the difference between two
groups in all pertinent experiments. Differences with $P<0.05$
were considered to be statistically significant.

Results
miR-27a is upregulated in liver cancer
patients who are obese
To investigate the role of miR-27a in liver cancer patients who
are obese, we first compared its expression levels between
clinical liver cancer tissues (T) and matched ANT from 15
cases of obese patients and 15 cases of nonobese patients.
By qRT-PCR, we showed that the miR-27a levels were
significantly higher in liver cancer samples than in the nontu-

tumor liver samples from all liver cancer patients (Figure 1A).
Interestingly, the overall expression level of miR-27a in

![Figure 1](https://www.dovepress.com/)

**Figure 1** miR-27a is upregulated in tumor tissue, serum and adipose tissue of obese liver cancer patients.

**Notes:** (A) qRT-PCR analysis of miR-27a expression in liver cancer tissue (T) compared with matched ANT from obese patients ($n=15$) and nonobese patients ($n=15$). (B) qRT-PCR analysis of miR-27a expression in plasma samples from obese patients ($n=15$), nonobese patients ($n=15$), and healthy individuals (controls, $n=10$). (C) qRT-PCR analysis of miR-27a expression in omental adipose tissue from obese patients ($n=15$), nonobese patients ($n=15$), and healthy individuals (controls, $n=15$). Each bar represents the mean ± SD of three independent experiments.

**Abbreviations:** qRT-PCR, quantitative real-time polymerase chain reaction; T, tissue; ANT, adjacent normal tissue; SD, standard deviation.
miR-27a targeting of FOXO1 promotes liver cancer in obese individuals

Dovepress

submit your manuscript | www.dovepress.com

Dovepress

OncoTargets and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 07-Aug-2019

For personal use only.

OncoTargets and Therapy 2015:8

whereas the addition of a miR-27a inhibitor blocked the 3T3-L1 cells compared with the control group at 24 or 48 hours, media were significantly enhanced in miR-27a-overproducing in Figure 2C and D, the miR-27a levels in HepG2 cells and 24 and 48 hours in these coculture experiments. As shown we detected the miR-27a level in HepG2 cells and media at the addition of a miR-27a inhibitor in the media. Moreover, Importantly, the increased cell viability was recovered by proliferation as measured by MTT assay (Figure 2B). To test our hypothesis, we conducted experiments to exam whether 3T3-L1 cells overexpressing miR-27a could stimulate the growth of liver cancer cells. We first established and confirmed stable miR-27a-overexpressed 3T3-L1 cell lines (Figure 2A). Cultured 3T3-L1 cells transfected with a miR-27a overexpression plasmid showed a significantly increased level in the cells and media, indicating that 3T3-L1 cells stably overexpressing miR-27a secreted a large of miR-27a into media. After 24 or 48 hours of incubation with the miR-27a-overproducing 3T3-L1 cells and control 3T3-L1 cells, we observed that HepG2 cells cocultured with miR-27a-overproducing 3T3-L1 cells showed a dramatic increase in proliferation as measured by MTT assay (Figure 2B). Importantly, the increased cell viability was recovered by the addition of a miR-27a inhibitor in the media. Moreover, we detected the miR-27a level in HepG2 cells and media at 24 and 48 hours in these coculture experiments. As shown in Figure 2C and D, the miR-27a levels in HepG2 cells and media were significantly enhanced in miR-27a-overproducing 3T3-L1 cells compared with the control group at 24 or 48 hours, whereas the addition of a miR-27a inhibitor blocked the miR-27a levels in the cells and media. These data indicated that the proliferation of HepG2 cells is attributable to the secretory miR-27a contained in the supernatant of miR-27a-overexpressed 3T3-L1 cells.

Because secretory miR-27a significantly affected cell proliferation in HepG2 cells, we hypothesized that miR-27a could function by affecting the cell cycle of liver cancer cells. We tested this hypothesis by flow cytometry. The results revealed that secretory miR-27a drastically decreased the percentage of cells in the G1/G0 peak and increased the percentage of cells in the S peak in HepG2 cells compared with control cells at 48 hours (Figure 3A). However, the addition of a miR-27a inhibitor dramatically increased the number of cells in the G1/G0 peak and decreased those in the S peak. Thus, secretory miR-27a may enhance the proliferation of liver cancer cells by promoting the G1/S cell cycle transition. FOXO1 is a putative tumor suppressor, and the expression of this gene is dysregulated in some cancers, including liver, breast, prostate, and endometrial cancers. Guttilla et al first reported that miR-27a directly targets various regions of the 3′-UTR to repress the endogenous expression of FOXO1 in breast cancer. To further study miR-27a transfer on a molecular level, we performed a target gene expression analysis of FOXO1. As predicted, western blotting revealed that the ectopic expression of miR-27a in HepG2 cells decreased the expression of FOXO1 proteins, whereas the addition of a miR-27a inhibitor increased its expression (Figure 3C and D). We also observed a similar result for the FOXO1 mRNA levels (Figure 3B). These data indicated that secretory miR-27a led to the decreasing of FOXO1 expression at the transcriptional and translational levels. The FOXO1 transcription factor orchestrates the regulation of genes involved in the cell cycle checkpoint, apoptotic response, and cellular metabolism. FOXO1 can regulate a series of genes that are relevant to the cell cycle at a transcriptional level, including p21, p27, and the CDK regulator cyclin D1. Using western blotting and qRT-PCR analysis, we observed that p21 and p27 protein and mRNA levels were downregulated and cyclin D1 protein and mRNA levels were upregulated in overexpressed miR-27a-3T3-L1 cocultured HepG2 cells compared with control cells (Figure 3B–D). However, the addition of a miR-27a inhibitor reversed this shift. Taken together, these results demonstrated that secretory miR-27a promoted liver cancer cell proliferation through the downregulation of the transcription factor FOXO1 and finally promoted the G1/S cell cycle transition by decreasing the cell cycle inhibitors p21 and p27, as well as increasing cell cycle regulator cyclin D1.

Secretory miR-27a promotes liver cancer cell proliferation through FOXO1

To test our hypothesis, we conducted experiments to examine whether 3T3-L1 cells overexpressing miR-27a could stimulate the growth of liver cancer cells. We first established and confirmed stable miR-27a-overexpressed 3T3-L1 cell lines (Figure 2A). Cultured 3T3-L1 cells transfected with a miR-27a overexpression plasmid showed a significantly increased level in the cells and media, indicating that 3T3-L1 cells stably overexpressing miR-27a secreted a large of miR-27a into media. After 24 or 48 hours of incubation with the miR-27a-overproducing 3T3-L1 cells and control 3T3-L1 cells, we observed that HepG2 cells cocultured with miR-27a-overproducing 3T3-L1 cells showed a dramatic increase in proliferation as measured by MTT assay (Figure 2B). Importantly, the increased cell viability was recovered by the addition of a miR-27a inhibitor in the media. Moreover, we detected the miR-27a level in HepG2 cells and media at 24 and 48 hours in these coculture experiments. As shown in Figure 2C and D, the miR-27a levels in HepG2 cells and media were significantly enhanced in miR-27a-overproducing 3T3-L1 cells compared with the control group at 24 or 48 hours, whereas the addition of a miR-27a inhibitor blocked the miR-27a levels in the cells and media. These data indicated that the proliferation of HepG2 cells is attributable to the secretory miR-27a contained in the supernatant of miR-27a-overexpressed 3T3-L1 cells.
miR-27a expression is correlated with FOXO1 in obese liver cancer patients

To further investigate this proposed regulation in liver cancer samples, we measured miR-27a using qRT-PCR analysis and performed immunohistochemical staining for FOXO1, p21, p27, and cyclin D1 on the paraffin-embedded cancer tissues (T) compared with matched ANT from 15 obese patients and 15 nonobese patients. As shown in Figures 1, 4, and 5, tumor tissues with high miR-27a expression exhibited low levels of FOXO1, p21, and p27 and high levels of cyclin D1. Additionally, matched ANTs with low miR-27a expression showed high levels of FOXO1, p21, and p27 and low levels of cyclin D1, revealing a strong link between miR-27a and proliferative potential. Remarkably, consistent with our in vitro experiments, higher miR-27a expression of obese liver cancer patients was significantly correlated with lower levels of FOXO1, p21, and p27 and higher levels of cyclin D1 compared with nonobese liver cancer patients with lower miR-27a expression. Collectively, these results strongly indicated that miR-27a expression is associated with liver cancer progression and prognosis, acting as a potential oncogenic biomarker involved in obesity-cancer communication.

Discussion and conclusion

Although the role of genetic alterations in oncogenes and tumor suppressor genes has been extensively studied, epigenetic mechanisms contributing to liver cancer development are less well characterized. The influence of miRNA on obesity-cancer communication is becoming increasingly recognized. In this study, we clearly demonstrated that miR-27a is more highly upregulated in cancer, plasma, and adipose samples from obese-liver cancer cases than nonobese liver cancer cases, and we reasoned that miR-27a excreted
from adipose tissue leaded to liver cancer development. It is well established that adipose tissue secretes a wide array of molecules. These adipokines, which are exclusively or partially secreted by adipocytes or stromal-vascular fraction cells, are likely to have a role in modulating the risk of cancer progression. Few studies examined the effect of adipocytes in liver cancer cell growth. In this study, we prepared miR-27a-overexpressing 3T3-L1 adipocytes and cocultured them with HepG2 liver cancer cells. Our study documented that the miR-27a derived from 3T3-L1 adipocytes had the ability to promote liver cancer cell proliferation.

If the movement of miR-27a is critical for liver cancer development, the transfer of silencing signals should be illustrated. MiR-27a is located on chromosome 19 and is overexpressed in liver cancer, breast cancer, gastric cancer, lung cancer, colorectal cancer, and pancreatic cancer. The increased expression of miR-27a was shown to promote tumor development by targeting multiple cellular factors, including FOXO1, ZBTB10, and Myt-1. All of these studies support the oncogenic role of miR-27a. Human Forkhead box O (FOXO) proteins (FOXO1, FOXO3a, FOXO4, and FOXO6) are key effectors of PI3K/Akt signaling and regulate many biological processes, such as cell cycle regulation, cell differentiation, tumorigenesis, and oxidative stress responses. The FOXO1 levels were higher in HCC patients with better prognosis (3-year survival) than in those with poor prognosis. Therefore, FOXO1 repression in HCC is likely to be associated with an unfavorable outcome. In this study, secretory miR-27a increased liver cancer cell proliferation through delay of the G1/S transition and decreased FOXO1 protein expression, which correlated with reduced expression of the genes regulated by FOXO1, including the cell-cycle inhibitors p21 and p27, and upregulation of the cell-cycle regulator...
cyclin D1. In agreement with our results, the downregulation of FOXO1 in human breast cancer cells can promote transformation and tumor progression.\textsuperscript{35} Moreover, it has been demonstrated that FOXO1 induces $G_1$ phase cell-cycle arrest in glioma cells and renal cell carcinoma due to inhibition of tumor suppressor phosphatase and tensin homolog deleted on chromosome ten (PTEN), via the upregulation of p27.\textsuperscript{36,37}

There are several potential mediators of obesity-related HCC that were discussed in previous reviews, such as lipotoxicity, changes in the gut microbiome, an imbalance in proinflammatory and anti-inflammatory cytokines, reduced adiponectin secretion, and increased leptin and stimulation of the insulin-like growth factor 1 (IGF-1) axis by hyperinsulinemia.\textsuperscript{9} These biomarkers may also explain the joint effect of obesity, with the traditional risk factors further increasing the risk of liver cancer. However, only a few prospective epidemiological studies have examined the association between inflammatory or metabolic biomarkers and risk of liver cancer in a general population. Having this information is important because evidence of the relation between obesity-related biomarkers and the risk of liver cancer may provide clues for understanding the underlying etiological mechanisms. In our study, we observed that the high miR-27a levels in obese liver cancer cases induced more liver cancer proliferation compared with nonobese liver cancer cases, indicating that miR-27a might become a potential biomarker for liver cancer diagnosis and prognosis. The main limitation of this study was the relatively small number of cases, which inevitably limited the precision of our estimates of relative risk between obesity and liver cancer. Therefore, the clinical significance and mechanism of miR-27a upregulation in obese liver cancer require further investigation.

**Conclusion**

Our current study demonstrates that obese adipose tissue-secreted miR-27a is upregulated in obese liver cancer...
tissues. Cocultured with miR-27a-overexpressing-3T3-L1 adipocytes drastically promotes liver cancer cell proliferation through the downregulation of the transcription factor FOXO1, promoting the G1/S cell cycle transition by decreasing the cell cycle inhibitors p21 and p27 and increasing the cell cycle regulator cyclin D1. These findings improve our understanding of the involvement of miR-27a in obesity–liver cancer communication and might provide a novel putative target for obese liver cancer diagnosis and therapy.

Acknowledgments

We thank Tissue Bank of China-Japan Union Hospital, Jilin University, for collection of the specimens used in this study. This study was supported by research grants from the Nature Science Foundation of Jilin Province, China (201215079).

Disclosure

The authors report no conflicts of interest in this work.

References